Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal quadrivalent CRM-197 conjugate vaccine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Meningococcal quadrivalent CRM-197 conjugate vaccine is a polysaccharide-protein conjugate vaccine designed to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine contains capsular polysaccharides from these four serogroups individually conjugated to the non-toxic mutant diphtheria toxin protein carrier CRM197. This conjugation enhances immunogenicity compared to unconjugated polysaccharide vaccines by inducing T-cell dependent immune responses and promoting immunological memory. The primary indication is active immunization against invasive meningococcal disease in individuals aged 2 months through 55 years. It does not protect against serogroup B infections. Clinical trials have demonstrated high immunogenicity and an acceptable safety profile across infants, children, adolescents, and adults[1][3][4][5].
- Brand names
- Menveo
- Other names
- meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on meningococcal quadrivalent CRM-197 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal quadrivalent CRM-197 conjugate vaccine.